Skip to main content
Quest Diagnostics

Determining the Immune Landscape of Patients with B- and T-cell Malignancies Utilizing Whole Transcriptome RNA Sequencing and TRUST4

AMP 2023

Association for Molecular Pathology

Salt Lake City, UT, Nov 14-18 2023

Poster presentation: Determining the Immune Landscape of Patients with B- and T-cell Malignancies Utilizing Whole Transcriptome RNA Sequencing and TRUST4

Authors: Williams N, Liu Y, Lohman B, Gerasimova A, Elzinga C, Tang T, Cacho D, Cure MS, Angeloni T, Van Ness M, Ma C, Racke F, Godsey J

Specialty: Oncology, Immunology

Related content

Publication
Identification of 22 novel BTK gene variants in B cell deficiency with hypogammaglobulinemia
Publication
The Evolving Clinical Testing Landscape of Genomic Aberrations in Solid
Publication
A rare case of therapy-related B-cell acute lymphoblastic leukemia arising from acute myeloid leukemia

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.